Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Neupogen (filgrastim), Neulasta (pegfilgrastim) - Important Safety Information from Amgen as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
28/08/2013
Problem Or Issue:
Important Safety Information communication from Amgen Ireland Limited on the association of Neupogen (filgrastim) with a risk of capillary leak syndrome in patients with cancer and in healthy donors.
Important Safety Information communication from Amgen Ireland Limited on the association of Neulasta (pegfilgrastim) with a risk of capillary leak syndrome in patients with cancer.
Important Safety Information – Neupogen (filgrastim), Neulasta (pegfilgrastim)
« Back
Date Printed: 07/05/2024